Liposomal	liposomal	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
advanced	advanced	O	O	O	O
Kaposi	kaposi	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
sarcoma	sarcoma	O	DISEASE	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
non-randomized	non-randomized	O	O	O	O
Phase	phase	O	O	O	O
II	ii	O	O	O	O
clinical	clinical	O	O	O	O
trial	trial	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
liposomal	liposomal	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
DaunoXome	daunoxome	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
AIDS	aids	O	DISEASE	OTHERS	I
related	related	O	O	O	O
Kaposi	kaposi	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
sarcoma	sarcoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Eleven	eleven	O	O	O	O
homosexual	homosexual	O	O	O	O
men	men	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
Kaposi	kaposi	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
sarcoma	sarcoma	O	DISEASE	OTHERS	I
were	were	O	O	O	O
entered	entered	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

Changes	changes	O	O	O	O
in	in	O	O	O	O
size	size	O	O	O	O
,	,	O	O	O	O
colour	colour	O	O	O	O
and	and	O	O	O	O
associated	associated	O	O	O	O
oedema	oedema	O	O	OTHERS	I
of	of	O	O	O	O
selected	selected	O	O	O	O
'	'	O	O	O	O
target	target	O	O	O	O
'	'	O	O	O	O
lesions	lesions	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
,	,	O	O	O	O
biochemical	biochemical	O	O	O	O
and	and	O	O	O	O
haematological	haematological	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
were	were	O	O	O	O
assessed	assessed	O	O	O	O
.	.	O	O	O	O

Ten	ten	O	O	O	O
subjects	subjects	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
was	was	O	O	O	O
achieved	achieved	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
,	,	O	O	O	O
of	of	O	O	O	O
whom	whom	O	O	O	O
two	two	O	O	O	O
subsequently	subsequently	O	O	O	O
relapsed	relapsed	O	O	O	O
.	.	O	O	O	O

Stabilization	stabilization	O	O	O	O
of	of	O	O	O	O
Kaposi	kaposi	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
sarcoma	sarcoma	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
remaining	remaining	O	O	O	O
six	six	O	O	O	O
,	,	O	O	O	O
maintained	maintained	O	O	O	O
until	until	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
period	period	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
drug	drug	O	O	O	O
was	was	O	O	O	O
generally	generally	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
few	few	O	O	O	O
mild	mild	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
main	main	O	O	O	O
problem	problem	O	O	O	O
encountered	encountered	O	O	O	O
was	was	O	O	O	O
haematological	haematological	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
three	three	O	O	O	O
subjects	subjects	O	O	O	O
experiencing	experiencing	O	O	O	O
severe	severe	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
neutrophil	neutrophil	O	O	O	O
count	count	O	O	O	O
<	<	O	O	O	O
0.5	0.5	O	O	O	O
x	x	O	O	O	O
10(9)/l	10(9)/l	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
small	small	O	O	O	O
patient	patient	O	O	O	O
sample	sample	O	O	O	O
,	,	O	O	O	O
liposomal	liposomal	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
an	an	O	O	O	O
effective	effective	O	O	O	O
and	and	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
agent	agent	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
Kaposi	kaposi	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
sarcoma	sarcoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

